scholarly journals Application of CLN-IgG/Pritumumab against COVID-19 Infectivity from the Aspect of Tumor-PIVIEMT Scheme

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Hugwil AV
Keyword(s):  
Monoclonal Antibody ◽  
Wound Healing ◽  
Clinical Trials ◽  
Stem Cell ◽  
Brain Tumor ◽  
Human Monoclonal Antibody ◽  
Tactile Sensor ◽  
Virus Infectivity ◽  
Virus Propagation ◽  
Tumor Patients

The touch/tactile sensor PIEZO1/2 and vimentin network is the critical conduit for COVID-19 virus infectivity. Coordination of PIEZO1/2 and vimentin network in regard to EMT/MET which is actual accordance of PIVEMT is critical for stem cell sustenance and wound healing of the injured cells and tissues in inflammation. On the contrary PIVIEMT discordance, deteriorated PIEZO1/2-Vimentin network, provokes pathogenic symptoms such as severe autoimmunopathies. From this aspect imminent treatment is necessary to recuperate the patients from onset of pathogens and/or neoplasms by use of chaperonic antibody that is able to restore/resile the pathogenic PIVIEMT as seen in the clinical trials against brain tumor patients with repetitive administration of the natural human monoclonal antibody CLN-IgG/Pritumumab. Targeting the virus conduit with the chaperonic antibody is highly expected for not only shutting down the virus infectivity but also augmentation of the antibody-directed vaccination against virus propagation.

scholarly journals PNR-17HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANT TO DELAY RADIATION IN PEDIATRIC EMBRYONAL BRAIN TUMOR PATIENTS

2016 ◽  
Vol 18 (suppl 3) ◽  
pp. iii10.1-iii10
Author(s):  
David Raleigh ◽  
Brian Tomlin ◽  
Benedict Del Buono ◽  
Erika Roddy ◽  
Katherine Sear ◽  
...  
Keyword(s):  
Stem Cell ◽  
Brain Tumor ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Tumor Patients ◽  
Embryonal Brain ◽  
Embryonal Brain Tumor

Race and Prognosis of Brain Tumor Patients Entering Multicenter Clinical Trials

1996 ◽  
Vol 19 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Joseph R. Simpson ◽  
Charles B. Scott ◽  
Marvin Rotman ◽  
Walter J. Curran ◽  
Louis S. Constine ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Brain Tumor ◽  
Tumor Patients ◽  
Multicenter Clinical Trials

scholarly journals Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues

2006 ◽  
Vol 17 (6) ◽  
pp. 327-329 ◽  
Author(s):  
BL Johnston ◽  
JM Conly
Keyword(s):  
Monoclonal Antibody ◽  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Infectious Complications ◽  
Solid Organ ◽  
Infection Rates ◽  
Hematopoietic Stem ◽  
The Many

In the July/August 2006 issue of this journal, the infectious complications associated with the use of infliximab, etanercept and adalimumab were reviewed (1). These represent only three of the many monoclonal antibodies either licensed or in clinical trials for therapeutic use in cancer and autoimmune disease or to prevent rejection in both solid organ and hematopoietic stem cell transplantation. While most of these agents have not been associated with increased infection rates, alemtuzumab and natalizumab have gained particular attention related to either the frequency or type of infection seen in some individuals who have received them.

Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 11522-11522 ◽  
Author(s):  
J. Kirkpatrick ◽  
A. Desjardins ◽  
J. J. Vredenburgh ◽  
J. A. Quinn ◽  
J. N. Rich ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumor ◽  
Glioblastoma Multiforme ◽  
Malignant Gliomas ◽  
Malignant Brain Tumor ◽  
Phase Iii ◽  
New Combination ◽  
Dramatic Improvement ◽  
Vegf Receptor ◽  
Tumor Patients

11522 Background: The prognosis for glioblastoma multiforme remains poor. Survival is generally limited to less than 1 year. Currently available standard treatments have not allowed, thus far, to prolong survival significantly. Response rates observed in clinical trials evaluating glioblastoma multiforme are usually less than 20%. Knowing that malignant gliomas have high concentrations of VEGF receptors, and the higher the VEGF receptor concentration, the worse the prognosis, we decided to evaluate the efficacy of bevacizumab in malignant brain tumor patients. Bevacizumab is a humanized IgG1 monoclonal antibody to VEGF, which is synergistic with chemotherapy for most malignancies. We performed a phase II study combining bevacizumab with irinotecan for patient with malignant gliomas and observed an unprecedented response rate of 63%. Methods: Building of those results, we decided to treat a number of our patients with voluminous unresectable disease with bevacizumab and temozolomide as an upfront regimen. Temozolomide is an oral methylating agent known effective for primary malignant brain tumor patients. A phase III trial, first presented at the ASCO meeting of 2003, demonstrated the efficacy of temozolomide for newly diagnosed glioblastoma multiforme patients, establishing temozolomide as the new standard of care. Given the known results with temozolomide as monotherapy and the combination of bevacizumab with irinotecan, we treated patients with temozolomide and bevacizumab upfront. Results: With this new combination, some patients demonstrated dramatic improvement clinically and radiographically. The combination has been well tolerated thus far, with no incidence of hemorrhage or arterial thrombosis observed. Conclusions: Results will be updated at the time of presentation. [Table: see text]

scholarly journals Daratumumab in untreated newly diagnosed multiple myeloma

2019 ◽  
Vol 10 ◽  
pp. 204062071989487 ◽  
Author(s):  
Nadine Abdallah ◽  
Shaji K. Kumar
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Clinical Trials ◽  
High Risk ◽  
Human Monoclonal Antibody ◽  
Proteasome Inhibitors ◽  
Immunomodulatory Drugs ◽  
Newly Diagnosed ◽  
Infusion Reactions

The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies. Daratumumab, a fully human monoclonal antibody targeting CD38, has shown clinical efficacy in relapsed/refractory multiple myeloma both as monotherapy and in combination with other drugs, including novel agents. More recently, promising results have been reported in patients with untreated newly diagnosed multiple myeloma (NDMM). Clinical trials thus far have shown enhanced efficacy and tolerability of several daratumumab-based combinations in both transplant ineligible and eligible patients, without compromising transplant ability. However, benefit in high-risk subpopulations is still unclear. A subcutaneous formulation of daratumumab has been introduced to decrease the risk of infusion reactions, with preliminary results showing non-inferior efficacy. The antimyeloma activity of daratumumab is achieved through multiple mechanisms including direct, Fc-dependent, and immunomodulatory mechanisms. Enhanced efficacy of daratumumab in combination with immunomodulatory drugs and proteasome inhibitors is supported by preclinical data showing synergism. This review will focus on the role of daratumumab in untreated NDMM patients, highlighting the results of major clinical trials, and listing ongoing trials that are evaluating various daratumumab-based combinations in this setting.

Sign in / Sign up

Export Citation Format

Share Document